Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN), a clinical-stage biotechnology company paying attention to extending the life expectancy of cancer patients, recently declared that it had priced an underwritten public contribution of a collective of 15,000,000.00 shares of common stock of the Company.
Jointly with warrants to buy up to 15,000,000.00 shares of ordinary stock of the Company, at a public offering cost of $0.8 for each share and the associated permit. Each merit will have a work out the price of $0.8 and will expire five years from the date of issuance.
The Company has also decided the underwriter a 30-day decision to buy up to 2,250,000.00 additional shares of general stock and other warrants to buy up to 2,250,000.00 shares of common stock, at the public offering worth, less underwriting discounts, and commissions.
The disgusting profits to Diffusion from this offering are predictable to be $12.00M, previous to deducting the underwriting rebates and commissions and other anticipated offering costs payable by Diffusion, arrogant no exercise of the underwriter’s alternative to buying additional securities and none of the warrants issued in this offering are exercised.
The offering is predictable to close on or about on January 22, of this year, focus on the satisfaction of customary finishing conditions.
Flow anticipates using the net profits from the offering, together with its existing cash and cash equivalents, to finance exploration and growth of its lead product candidate, transcrocetinate sodium, also known as trans sodium crocetinate (TSC), counting clinical check activities, and for general corporate purposes.
The Company is offering the securities depicted above following a registration declaration formerly filed with and declared successful by the Securities and Exchange Commission (the “SEC”) on January 17, of this year.